{"id":"tegoprazan-50-mg-tablets-orally-qd","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4297583","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unlike proton pump inhibitors (PPIs) that irreversibly block the H+/K+-ATPase, tegoprazan competitively inhibits this pump in a potassium-dependent manner, allowing for more rapid onset and offset of acid suppression. This mechanism may provide faster symptom relief and potentially fewer drug-drug interactions compared to traditional PPIs. Tegoprazan is used to treat acid-related gastrointestinal disorders by maintaining elevated gastric pH.","oneSentence":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:29.386Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Acid-related gastrointestinal disorders"}]},"trialDetails":[{"nctId":"NCT05647278","phase":"PHASE4","title":"Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)","status":"COMPLETED","sponsor":"Zhang Xiaofeng,MD","startDate":"2023-11-01","conditions":"Helicobacter Pylori Infection","enrollment":370},{"nctId":"NCT04639804","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-06-06","conditions":"Healthy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tegoprazan 50 mg, tablets, orally, qd","genericName":"Tegoprazan 50 mg, tablets, orally, qd","companyName":"Zhang Xiaofeng,MD","companyId":"zhang-xiaofeng-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Acid-related gastrointestinal disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}